Authors: Chris Melore Study Finds April 25, 2022 Antibiotics that are helping to treat patients with COVID-19 may actually be fueling a concerning rise in the number of superbugs infecting people worldwide. Researchers in the United States have found that cases of antibiotic-resistant bacterial infections are going up in comparison to the last year before […]
Some therapies have been shown to work in clinical studies and other research Authors: Jared S. Hopkins Updated Mar. 31, 2022 3:12 pm ET Talhe Wall Street Journal The Food and Drug Administration authorized the first antiviral pills to treat Covid-19 from Pfizer Inc. and Merck & Co. and partner Ridgeback Biotherapeutics LP in December. The authorizations came after each drugmaker’s […]
Two new studies propose the first model for diagnosing, indexing and monitoring Post-Acute Sequelae of COVID-19 (PASC), also known as long COVID or long haul COVID. The findings also provide a framework for understanding the cause of, and potential treatment for, long COVID. Long COVID is believed to affect as many as 30 percent of […]
Italian study of long-COVID patients suggests those infected with the Alpha variant experienced different neurological and emotional symptoms compared to those who contracted the original form of SARS-CoV-2 Authors: EUROPEAN SOCIETY OF CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASES 24-MAR-2022 New research to be presented at this year’s European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) […]
Some therapies have been shown to work in clinical studies and other research Authors: Jared S. Hopkins Mar. 21, 2022 4:47 pm ET The Wall Street Journal The Food and Drug Administration authorized the first antiviral pills to treat Covid-19 from Pfizer Inc. and Merck & Co. and partner Ridgeback Biotherapeutics LP in December. The authorizations came after each drugmaker’s pill […]
The I-TECH Randomized Clinical Trial February 18, 2022 Authors: Steven Chee Loon Lim, MRCP1; Chee Peng Hor, MSc2,3; Kim Heng Tay, MRCP4; et alAnilawati Mat Jelani, MMed5; Wen Hao Tan, MMed6; Hong Bee Ker, MRCP1; Ting Soo Chow, MRCP7; Masliza Zaid, MMed8; Wee Kooi Cheah, MRCP6; Han Hua Lim, MRCP9; Khairil Erwan Khalid, MRCP10; Joo Thye Cheng, MRCP2; Hazfadzila Mohd Unit, MRCP11; Noralfazita An, MMed12; Azraai Bahari Nasruddin, MRCP13; Lee Lee Low, MRCP14; Song Weng Ryan Khoo, MRCP15; Jia Hui Loh, MRCP16; Nor Zaila Zaidan, MMed17; Suhaila Ab Wahab, MMed18; Li Herng Song, MD19; Hui Moon Koh, MClinPharm20; Teck Long King, BPharm21; Nai Ming Lai, MRCPCH22; Suresh Kumar Chidambaram, MRCP4; Kalaiarasu M. Peariasamy, MSc23; for the I-TECH Study Group Article Information Abstract Importance Ivermectin, an inexpensive and widely available antiparasitic drug, is […]
AuthorsAlexander Supadya,c,d and Robert Zeiserb Lancet Respir Med. 2022 Feb 3doi: 10.1016/S2213-2600(22)00021-2 [Epub ahead of print]PMCID: PMC8813061PMID: 35123659 Mortality is high among patients with severe COVID-19 who require invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO).1, 2 Therefore, further specific treatment options for these patients are urgently needed. Early in the COVID-19 pandemic, Janus kinase (JAK) inhibitors were identified as potential therapeutic agents […]
Authors: Patrick J Lindsay, a Rachel Rosovsky, b Edward A Bittner, c and Marvin G. Chang c ABSTRACT Introduction COVID-19-associated coagulopathy (CAC) is a well-recognized hematologic complication among patients with severe COVID-19 disease, where macro- and micro-thrombosis can lead to multiorgan injury and failure. Major societal guidelines that have published on the management of CAC are based on consensus of expert opinion, with […]
Authors: Waldemar Kanczkowski. Katja Evert. Marlena Stadtmüller, Martina Haberecker, Laura Laks, Lan-Sun Chen, et al. Published:November 18, 2021DOI:https://doi.org/10.1016/S2213-8587(21)00291-6PlumX Metrics COVID-19 develops due to infection with SARS-CoV-2, which particularly in elderly with certain comorbidities (eg, metabolic syndrome)1 can cause severe pneumonia and acute respiratory distress syndrome. Some patients with severe COVID-19 will develop a life-threatening sepsis with […]
For hospitalized patients already taking other proven COVID-19 drugs, pill further reduces chance of death Authors: KAI KUPFERSCHMIDT 3 MAR 2022 1:20 PM Baricitinib, an oral drug that dampens an overactive immune system and is commonly used by people with rheumatoid arthritis, reduced hospitalized COVID-19 patients’ risk of dying by 13%, investigators of the world’s […]